Abstract:Silymarin, a phyto-constituent derived from the plant Silybum marianum, has been widely acknowledged for its hepatoprotective activities. Nevertheless, its clinical utility is adversely hampered by its poor water-solubility and its limited oral bioavailability. The aim of this study was to investigate the efficacy of phospholipid-based phytosomes for enhancing the oral bioavailability of silymarin. The phytosomes were prepared using the solvent evaporation technique and were optimized using a full factorial design. The optimized silymarin phytosomal formulation was then characterized for particle size, surface morphology, aqueous solubility, and in vitro drug release. Furthermore, in vivo antioxidant activity, hepatoprotective activity and oral bioavailability of the optimized formula were investigated in a rat model. The prepared silymarin phytosomes were discrete particles with a porous, nearly smooth surface and were 218.4 ± 2.54 nm in diameter. In addition, the optimized silymarin phytosomal formulation showed a significant improvement in aqueous solubility (~360 μg/mL) compared to pure silymarin and manifested a higher rate and extent of silymarin release from the optimized formula in dissolution studies. The in vivo assessment studies revealed that the optimized silymarin phytosomal formulation efficiently exerted a hepatoprotective effect in a CCl4-induced hepatotoxicity rat model via restoring the normal levels of antioxidant enzymes and ameliorating cellular abnormalities caused by CCl4-intoxication. Most notably, as compared to pure silymarin, the optimized silymarin phytosomal formulation significantly improved silymarin oral bioavailability, as indicated by a 6-fold increase in the systemic bioavailability. Collectively, phytosomes might represent a plausible phospholipid-based nanocarrier for improving the oral bioavailability of phyto-constituents with poor aqueous solubility.

Study on the Bioavailability of HP-β-CD Silymarin in Rats

Binary lipids-based nanostructured lipid carriers for improved oral bioavailability of silymarin.

Silymarin Glyceryl Monooleate/Poloxamer 407 Liquid Crystalline Matrices: Physical Characterization and Enhanced Oral Bioavailability

Pharmacokinetics and Tissue Distribution of Silybin Gelatin Microspheres in Vivo in Rats

In vivo evaluation of silybin nanosuspensions targeting liver.

Enhanced Bioavailability and Efficacy of Silymarin Solid Dispersion in Rats with Acetaminophen-Induced Hepatotoxicity

Enhanced Bioavailability of Silymarin by Self-Microemulsifying Drug Delivery System

Nanostructured Lipid Carriers for Parenteral Delivery of Silybin: Biodistribution and Pharmacokinetic Studies.

In vitro and in vivo evaluation of a self-microemulsifying drug delivery system for silybin

<i>In vitro</i>and<i>in vivo</i>evaluation of silybin nanosuspensions for oral and intravenous delivery

Enhanced bioavailability and hepatoprotective effect of silymarin by preparing silymarin-loaded solid dispersion formulation using freeze-drying method

Preparation and in Vitro and in Vivo Evaluation of Silymarin Self-Microemulsifying Concentrated Microemulsion

In vitro assessment of the effects of silybin on CYP2B6-mediated metabolism

Phytosomes as a Plausible Nano-Delivery System for Enhanced Oral Bioavailability and Improved Hepatoprotective Activity of Silymarin

Preclinical Validation of Silibinin/albumin Nanoparticles As an Applicable System Against Acute Liver Injury.

A Comparative Study on the Stability of Silybin and That in Silymarin in Buffers and Biological Fluids

A comparative study on the preparation and evaluation of solubilizing systems for silymarin

Comparative study of different silymarin formulations: formulation, characterisation and in vitro/in vivo evaluation

Nanocrystal Formulation to Enhance Oral Absorption of Silybin: Preparation, In Vitro Evaluations, and Pharmacokinetic Evaluations in Rats and Healthy Human Subjects

Preparation of silymarin suspension and evaluation of its stability and release

Preliminary Toxicology Evaluation of Silymarin